Avid Bioservices Inc (CDMO)

[biopharm]

After reading this patent more closely....this "upstream" looks like it could be referring to Phosphatidylserine and now more interesting is the Epiontis collaboration with Peregrine and Turbachova laboratory

Epiontis scooped up by Precision for Medicine for PS Targeting biomarkers related reasons.....

Precision for Medicine Acquires Epiontis—a Leading Immune Monitoring and Epigenetic Technology Service Provider
ADDITION OF BERLIN-BASED LAB EXPANDS PRECISION’S LARGE ARRAY OF IMMUNE MONITORING CAPABILITIES AND BOLSTERS GLOBAL FOOTPRINT

Bethesda, MD and Berlin, Germany – October 4th, 2017
...
.
https://www.bacb.de/precision-for-medicine-acquires-epiontis/

--------

We clearly have seen Foundation for Medicine and Peregrine and Vanderbilt collaborations

5. PPHM+VANDERBILT+PRECISIONMEDICINE+PROVIDENCECC: 4-3-17/1pm #CT159/25 (Session: Ph2/3 Clinical Trials in Progress), “IFN-y Analysis In Blood & Tissue as a Potential Prognostic and/or Predictive Biomarker” (abstract embargoed, Sunrise Biomarker #3?)
..
..
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=129196894

"We are very excited to be joining the Precision for Medicine family," explains Dr. Sven Olek, co-founder and chief executive officer of Epiontis. "Becoming part of Precision allows us to provide our clients with a complete, customized immune monitoring solution, and also gives us the opportunity to introduce our proprietary epigenetic technology and expertise to a broader customer base. Together, Precision and Epiontis are able to offer innovative life sciences clients many options for immune monitoring, including our patented epigenetic markers and global flow cytometry capabilities."
https://www.google.com/amp/s/www.cnbc.com/amp/2017/10/04/pr-newswire-precision-for-medicine-acquires-leading-immune-monitoring-and-epigenetic-technology-service-provider-epiontis.html

----

PEREGRINE AND EPIONTIS
.
...
Filed: April 3, 2017
Publication date: August 17, 2017
Inventors: Sven OLEK, Ivana TÜRBACHOVA - deceased

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=134747702

https://investorshub.advfn.com/boards/replies.aspx?msg=134747702

--------

Do not forget Epiontis + Precision for Medicine + Peregrine collaborations

-------

Bird & Bird advises Precision Medicine Group on the acquisition of Epiontis
09 October 2017

Bird & Bird LLP advises Precision Medicine Group, a scientific services company helping life science innovators develop medical products, on the acquisition of all shares in Epiontis GmbH, a leading immune monitoring and epigenetic technology service provider based in Berlin.

The acquisition will allow Precision for Medicine to expand on its immune monitoring capabilities with Epiontis’s epigenetic technology, and strengthen its global footprint in the rapidly expanding precision medicine sector.

The Bird & Bird team advised Precision for Medicine on the due diligence, signing and closing of the transaction, including IP patent due diligence and regulatory advice regarding the life sciences aspects of the deal.

Stefan Münch (Corporate/M&A, Munich) led the transaction on the German law aspects, assisted by counsel Stephan Kübler and associates Michael Gassner and Benedikt Weiss (both Corporate/M&A, Munich), partner Ralph Panzer and associate Julia Gottinger (both Employment, Munich), counsel Gerrit Wiedow (Employment, Hamburg), partners Michael Alt, Christopher Maierhöfer and associate Marie-Theres Schmid (all Patents, Munich), partner Markus Körner and counsel Thomas Urband (both Trademarks, Munich), partner Alexander Csaki and associate Clarissa Junge-Gierse (both Life Sciences/Regulatory, Munich) and partner Michael Jünemann (Finance, Frankfurt). Bird & Bird London partner Ali Ramadan and associate Hannah Fletcher (both Corporate/M&A, London) also assisted on the UK law issues. Legal in-house advisors were General Counsel John Mariano and Senior Counsel Rita Khoobchandani.

https://www.twobirds.com/en/news/press-releases/2017/germany/bird-and-bird-advises-precision-medicine-group-on-the-acquisition-of-epiontis